Risk factors and natural history of breast cancer in younger Chinese women

Park, Yeon Hee; Lee, Hang-Mei; Chan, Amy B.W.; Chan, Emily; Chan, Max Kam-Kwan; Chan, K. S.; Chan, Sharon Ww; Cheung, Foon-Yiu; Cheung, PT; Choi, Peter; Chor, Josette S.Y.; Foo, William; Kwan, Wing-Hong; Law, Stephen C.K.; Li, Lawrence PK; Tsang, J W-H; Tung, Yuk Ying; Wong, Lo; Wong, Tak Ming; Yau, C. C.; Yau, Tsz‐Kok; Zee, Benny

doi:10.5306/wjco.v5.i5.1097

Cited by 19 publications

(27 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In our series, this frequency was 24.42%, thus exceeding the frequency of the Occidental studies and concordant with the Maghreb studies. The average age of onset of breast cancer in the literature is often after 30 years (1,5,6) , which is consistent with our study with an average of 35.6 years. Several risk factors other than age are commonly associated with breast cancer in young women, including early menarche, nulliparity, first late pregnancy, and a family history of breast cancer.…”

Section: Discussionsupporting

confidence: 81%

“…In the pathological study, invasive breast carcinoma no special type is the most frequent histological type. It is all the more aggressive because it is associated with an SBR III grade, lymph node invasion, negative hormone receptors and overexpression of HER2 (1,4,5,6) . In our series, invasive breast carcinoma no special type was by far the most frequent (82.3%).…”

Section: Discussionmentioning

confidence: 99%

“…In our study, we chose an age limit of 40 years. The incidence of breast cancer in young women varies between 1.3 and 25% (1,4,5,6) . In our series, this frequency was 24.42%, thus exceeding the frequency of the Occidental studies and concordant with the Maghreb studies.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Molecular Profile of Breast Cancer in Young Women in the Marrakech Region, Morocco: Experience of the Oncology Department CHU Mohamed VI Marrakech, Morocco

Bensallam¹,

Oumghar²,

Elomrani³

et al. 2017

IAM

View full text Add to dashboard Cite

Breast cancer in young women is increasing. The objective of this work was to analyze the epidemiological, clinical, therapeutic and prognostic characteristics of breast cancer in young women under 40 years. Through a retrospective study spread over five years from 1 January 2008 to 31 December 2012 and held at the Radiation Oncology Service of the University Hospital Mohammed VI Marrakech, we identified 272 cases of breast cancer in patients aged 40 years and under. The frequency of breast cancer in young women under 40 years was 24.42%. The average age was 35.6 years. The pauciparity and nulliparity were predominant (60.6%). 8 % had a family history of breast cancer. The self-examination of a nodule was predominant (93%). Tumors classified T2 were the most frequent (45%), followed by T4 tumors (29%).17% were metastatic immediately with predominant hepatic localizations (37.6%). It was Invasive breast carcinoma no special type (NST) in 82.3% of cases, with a predominance of SBR grades II and III (96%). Hormone receptors were positive in 68% of cases and HER2 overexpressed in 29 % of cases. 218 patients underwent surgery, which was radical in 68% and conservative in 21%. 149 had a locoregional irradiation. 71% received adjuvant chemotherapy with a predominance of FAC60 protocol (35%). Hormonotherapy was prescribed in 78% of cases with positive hormone receptors and trastuzumab in 73.8 % of patients over expressing HER2. After a median follow-up of 8.1 months, 41.4 % had relapses. Overall survival at three years was 70%, and the relapse free survival was 62%. Our study joins the data in the literature advocating more advanced forms and worse prognosis of breast cancer in young patients.

show abstract

Section: Discussionsupporting

confidence: 81%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Molecular Profile of Breast Cancer in Young Women in the Marrakech Region, Morocco: Experience of the Oncology Department CHU Mohamed VI Marrakech, Morocco

Bensallam¹,

Oumghar²,

Elomrani³

et al. 2017

IAM

View full text Add to dashboard Cite

show abstract

“…These mainly involve surgery followed by post-operative adjuvant therapies that may include chemotherapy, radiotherapy, endocrine therapy and/or targeted therapy. Although less than 15% of patients were reported to be diagnosed before age 40 [2], a higher proportion of these patients were subjected to adjuvant cytotoxic therapy [2].…”

Section: Introductionmentioning

confidence: 99%

Menopausal symptoms in relationship to breast cancer-specific quality of life after adjuvant cytotoxic treatment in young breast cancer survivors

Park

Pang

Liem

et al. 2020

Health Qual Life Outcomes

Self Cite

View full text Add to dashboard Cite

Introductions: For young premenopausal breast cancer patients, adjuvant chemotherapy may cause menstrual disruptions and premature menopause, which may in turn impair their quality of life (QoL). In this study among young breast cancer survivors who have undergone adjuvant chemotherapy, the objectives were to assess posttreatment menopausal symptoms and their associated factors, and to correlate these symptoms with breast cancerspecific QoL.Methods: The study population included premenopausal young Chinese women with early-stage breast cancer who had undergone adjuvant chemotherapy between 3 and 10 years prior to enrolling into this study. At study entry, patients' characteristics and clinical features were collected; each patient had detail menstrual history collected and each filled in MENQOL and FACT-B + 4 questionnaires.Results: Two hundred eighty eligible patients were recruited. For adjuvant chemotherapy, 92% received anthracyclines and 28% received taxanes; 76% received adjuvant tamoxifen. At a median of 5.0 years from initial cancer diagnosis, 49 and 11% had become post-and peri-menopausal respectively. MENQOL at study entry revealed that physical domain score was worse in overweight/obese patients (mean scores for underweight/normal vs overweight/obese: 2.65 vs 2.97, p = 0.0162). Vasomotor domain score was worse in those who received taxanes or tamoxifen (taxane vs non-taxane: 2.91 vs. 2.35, p = 0.0140; tamoxifen vs no tamoxifen: 2.75 vs. 2.34, p = 0.0479). Sexual domain score was worse among those who had become peri/post-menopausal (peri/postmenopausal vs premenopausal: 2.82 vs. 2.29, p = 0.0229). On the other hand, patients who utilized traditional Chinese medicine had significantly worse scores for vasomotor, psychosocial and physical domains. Further, there was a significant association between MENQOL scores and FACT-B + 4 scores; less severe symptoms in the MENQOL domains were associated with better QoL scores in FACT-B + 4 physical, functional, psychosocial and emotional well-being, Breast Cancer Subscale, Arm Subscale and FACT-B total score.

show abstract

“…In another study by Anders et al, among women with early-stage breast cancer, younger patients were found to have larger tumors of higher grade, more lymph node positivity, lower estrogen receptor expression and higher HER2/neu overexpression, and eventually worse disease-free survival (DFS) 7. In a Chinese study, invasive breast cancer in younger patients was associated with more aggressive pathological features, such as a higher percentage of grade 3 histology, a higher proportion of tumors with lymphovascular invasion, and a more multifocal disease 8. On the other hand, a study conducted in Switzerland involving 2997 breast cancer patients assessed the impact of age at diagnosis on clinical presentation and other variables.…”

Section: Introductionmentioning

confidence: 99%

Younger age is an independent predictor of worse prognosis among Lebanese nonmetastatic breast cancer patients: analysis of a prospective cohort

Chediak¹,

Alameddine²,

Hakim³

et al. 2017

BCTT

View full text Add to dashboard Cite

BackgroundSeveral retrospective studies have reported that younger age at presentation is associated with a worse prognosis for nonmetastatic breast cancer patients. In this study, we prospectively assessed the association between different baseline characteristics (age, tumor characteristics, mode of treatment, etc) and outcomes among newly diagnosed nonmetastatic Lebanese breast cancer patients.MethodsWe recruited a sample of 123 women newly diagnosed with nonmetastatic breast cancer presenting to American University of Beirut Medical Center. Immunohistochemical, molecular (vitamin D receptor, methylene tetrahydrofolate reductase polymorphisms), and genetic assays were performed. Patient characteristics were compared by age group (<40 and ≥40 years). A Cox regression analysis was performed to evaluate the variables affecting the disease-free survival (DFS). Outcome data were obtained, and DFS was estimated.ResultsAmong the 123 patients, 47 were 40 years of age or younger, and 76 were older than 40 years. Median follow-up duration was 58 months. Nine out of 47 patients <40 years (19.1%) experienced disease relapse in contrast to four out of 76 patients >40 years (5.2%). A wide immunohistochemical panel included Ki-67, cyclin B1, p53, platelet-derived growth factor receptor, and vascular endothelial growth factor receptor, and did not reveal any significant difference in these markers between the two age groups. Older patients had a larger percentage of Luminal A than younger patients. On multivariate analysis including age, stage, grade, and subtype, only age <40 and stage were significantly associated with shorter DFS with hazard ratios of 4 (p=0.03, 95% confidence interval [CI]: 1.1–13.5) and 3 (p=0.03, 95% CI: 0.8–14.9), respectively. The estimated 5-year DFS for patients >40 years was 90%, and for patients <40 years was 37%.ConclusionBeing <40 years old was an independent risk factor for recurrence in this cohort of patients.

show abstract

Risk factors and natural history of breast cancer in younger Chinese women

Abstract: Younger patients in Hong Kong are more likely to encounter risk factors associated with breast cancer development and have more aggressive tumours than their older counterparts.

Cited by 19 publications

References 32 publications

Molecular Profile of Breast Cancer in Young Women in the Marrakech Region, Morocco: Experience of the Oncology Department CHU Mohamed VI Marrakech, Morocco

Molecular Profile of Breast Cancer in Young Women in the Marrakech Region, Morocco: Experience of the Oncology Department CHU Mohamed VI Marrakech, Morocco

Menopausal symptoms in relationship to breast cancer-specific quality of life after adjuvant cytotoxic treatment in young breast cancer survivors

Younger age is an independent predictor of worse prognosis among Lebanese nonmetastatic breast cancer patients: analysis of a prospective cohort

Contact Info

Product

Resources

About